Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma
Immunology · 2023-06 · 169 (2) · 204-218
DOI: 10.1111/imm.13624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, online erschienen am 25.01.2023. Verfasst von Lin Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, People's Rep…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Receptors, Chimeric Antigen, Liver Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
Although the pre‐clinical study of chimeric antigen receptor (CAR)‐natural killer (NK) cell was effective against various tumours, immunosuppression mediated by tumour microenvironment hampers their application and several efforts have been explored to improve their effect in combating solid tumours. Glypican 3 (GPC3) is a promising target for hepatocellular carcinoma (HCC), and CAR‐T cells targeting GPC3 have been tested in clinical trials. Based on an affinity‐enhanced antibody (hYP7) targeting GPC3, we constructed GPC3‐CAR‐NK cells to explore their potential function in the treatment of HCC. We found that patients with HCC secreted high levels of soluble programmed death‐ligand 1 (sPD‐L1), which inhibits the function of CAR‐NK cells targeting GPC3. In addition, we combined high‐affinity sPD‐L1 variant (L3C7c‐Fc) with GPC3‐CAR‐NK cells to solve the problem of GPC3‐CAR‐NK inhibition. Our studies demonstrated that L3C7c‐Fc could enhance the therapeutic effect of CAR‐NK cells by reversing the suppression of sPD‐L1, which provides the experimental evidence for the subsequent development of HCC immunotherapy strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.
- Department of Hepatobiliary surgery, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, People's Republic of China.
- State Key Laboratory of Respiratory Disease, Center of Infection and Immunity, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Guangzhou, People's Republic of China.
- Department of Pathology, Affiliated Drum Tower Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
- Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
ORCID-Profile: Lin Chen
Förderung
- Intramural NIH HHS
Zitieren
APA
Chen, L., Liu, S., Adah, D., Sun, Q., Liang, Z., Ho, M., & Sun, B. (2023). Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma. Immunology, 169(2), 204-218. https://doi.org/10.1111/imm.13624
Vancouver
Chen L, Liu S, Adah D, Sun Q, Liang Z, Ho M, et al. Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma. Immunology. 2023;169(2):204-218. doi:10.1111/imm.13624
BibTeX
@article{Chen2023,
author = {Chen, Lin and Liu, Siyuan and Adah, Dickson and Sun, Qingyang and Liang, Zhaoduan and Ho, Mitchell and Sun, Beicheng},
title = {Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma},
journal = {Immunology},
year = {2023},
volume = {169},
number = {2},
pages = {204--218},
doi = {10.1111/imm.13624}
}
EUVIMED